Free standard shipping on all orders.
SinuSonic Celebrates First Anniversary with Launch of Latest Independent Study for Treatment of Eustachian Tube Dysfunction, Sinus Pain and Pressure

COLUMBIA, S.C., October 1, 2020 – Developers of SinuSonic, a first of its kind medical device for natural relief of nasal congestion using acoustic humming and oscillating pressure, are celebrating the product’s first anniversary on the market providing a revolutionary, economical solution to congestion. To mark this occasion, SinuSonic is announcing its latest independent medical study in coordination with researchers at the Medical University of South Carolina. Participants will aid researchers in determining the efficacy of Sinusonic for treating Eustachian Tube Dysfunction (ETD) and sinus pain and pressure.

“These conditions are thought to occur due to an inability for patients equalize pressure in their middle ear or sinus cavities. This pressure builds up and causes pain,” explained Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and co-Medical Director at SinuSonic. “Traditional treatments usually require more invasive procedures to alleviate the pressure build up, but SinuSonic may equalize these pressures simply by using acoustic energy and oscillating pressure.”

Originally developed to treat chronic nasal congestion without drugs or mess, SinuSonic offers patients the ability to treat moderate to severe nasal congestion by simply breathing into a device, triggering the application of gentle acoustic vibrations and light resistant pressure to provide natural relief. Results from an independent study published in the February 2020 edition of the International Forum of Allergy and Rhinology found more than 80 percent of trial subjects experienced clinically and statistically significant improvements in self-reported nasal congestion scores. Additionally, the SinuSonic device was found to be safe and well tolerated and improved objective AND subjective outcomes in chronic rhinitis. In fact, 87.5% of subjects would recommend SinuSonic to a friend or family member.

“When you’re bringing a new product to market and potentially expanding the market on its uses of treatment, providing the public with tangible facts, medical study results and validated support from specialty doctors in this arena is critical,” stated Dr. Zachary Soler, Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina and co-Medical Director of SinuSonic. “The results from this study have tremendous potential in providing widespread relief for health issues affecting millions of Americans daily.”

Since launching in July 2019, SinuSonic is being used in all 50 states. To learn more or purchase a SinuSonic device, visit www.SinuSonic.com.